Pasar al contenido principal

REGULACION DE LA LONGEVIDAD Y ENFERMEDADES ASOCIADAS POR HORMONAS ESTEROIDEAS SULFATADAS

PID2020-120463RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD PABLO DE OLAVIDE, DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Asparagus Fructans as Emerging Prebiotics

  • Hamdi, Amel
  • Viera Alcaide, Isabel
  • Guillén Bejarano, Rafael
  • Rodríguez-Arcos, Rocío
  • Muñoz-Ruiz, Manuel Jesús
  • Monje-Moreno, José Manuel
  • Jiménez Araujo, Ana
19 Páginas.-- 7 Figuras.-- 3 Tablas, Commercial fructans (inulin and oligofructose) are generally obtained from crops such as chicory, Jerusalem artichoke or agave. However, there are agricultural by-products, namely asparagus roots, which could be considered potential sources of fructans. In this work, the fructans extracted from asparagus roots and three commercial ones from chicory and agave were studied in order to compare their composition, physicochemical characteristics, and potential health effects. Asparagus fructans had similar chemical composition to the others, especially in moisture, simple sugars and total fructan contents. However, its contents of ash, protein and phenolic compounds were higher. FTIR analysis confirmed these differences in composition. Orafti®GR showed the highest degree of polymerization (DP) of up to 40, with asparagus fructans (up to 25) falling between Orafti®GR and the others (DP 10-11). Although asparagus fructan powder had a lower fructan content and lower DP than Orafti®GR, its viscosity was higher, probably due to the presence of proteins. The existence of phenolic compounds lent antioxidant activity to asparagus fructans. The prebiotic activity in vitro of the four samples was similar and, in preliminary assays, asparagus fructan extract presented health effects related to infertility and diabetes diseases. All these characteristics confer a great potential for asparagus fructans to be included in the prebiotics market., This research was funded by grant AGL2017-82428-R and PID2020-120463RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; by grant PDC2021-121674-I00 funded by MCIN/AEI/10.13039/501100011033 by “European Union NextGenerationEU/PRTR”, and by European Union “NextGenerationEU” by the grant “Margarita Salas” for the Requalification of the Spanish university system 2021-2023 convened by the University Pablo de Olavide (Sevilla, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer’s Disease

  • Esteban-Martos, Álvaro
  • Brokate-Llanos, Ana María
  • Real, Luis Miguel
  • Melgar-Locatelli, Sonia
  • Rojas, Itziar de
  • Castro-Zavala, Adriana
  • Bravo, María Jose
  • Mañas-Padilla, María del Carmen
  • García-González, Pablo
  • Ruiz-Galdon, Maximiliano
  • Pacheco-Sánchez, Beatriz
  • Polvillo Hernández, Rocío
  • Rodriguez de Fonseca, Fernando
  • González, Irene
  • Castilla-Ortega, Estela
  • Muñoz-Ruiz, Manuel Jesús
  • Rivera, Patricia
  • Reyes-Engel, Armando
  • Ruiz, Agustín
  • Royo, José Luis
Genome-wide association studies (GWAS) constitute a powerful tool to identify the different biochemical pathways associated with disease. This knowledge can be used to prioritize drugs targeting these routes, paving the road to clinical application. Here, we describe DAGGER (Drug Repositioning by Analysis of GWAS and Gene Expression in R), a straightforward pipeline to find currently approved drugs with repurposing potential. As a proof of concept, we analyzed a meta-GWAS of 1.6 × 107 single-nucleotide polymorphisms performed on Alzheimer’s disease (AD). Our pipeline uses the Genotype-Tissue Expression (GTEx) and Drug Gene Interaction (DGI) databases for a rational prioritization of 22 druggable targets. Next, we performed a two-stage in vivo functional assay. We used a C. elegans humanized model over-expressing the Aβ1-42 peptide. We assayed the five top-scoring candidate drugs, finding midostaurin, a multitarget protein kinase inhibitor, to be a protective drug. Next, 3xTg AD transgenic mice were used for a final evaluation of midostaurin’s effect. Behavioral testing after three weeks of 20 mg/kg intraperitoneal treatment revealed a significant improvement in behavior, including locomotion, anxiety-like behavior, and new-place recognition. Altogether, we consider that our pipeline might be a useful tool for drug repurposing in complex diseases., This work was mainly financed by Programa Operativo FEDER funds from the European Union through grant UMA20-FEDERJA-133. We thank Fundacion SantÁngela for co-funding with grant 83/23.04.2021. P.G.-G. is supported by the CIBERNED employment plan CNV-304-PRF-866. CIBERNED is integrated into Instituto de Salud Carlos III. I.d.R is supported by a national grant from the Instituto de Salud Carlos III FI20/00215. A.R. is supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240, and PI19/01301. A.M.B.-L. and M.J.M. were funded by grant PID2020-120463RB-I00 funded by the Spanish Ministerio de Ciencia e Innovación. A.C.-Z. holds a postdoctoral research contract from Secretaría General de Universidades, Investigación y Tecnología–Junta de Andalucía (POSTDOC21_00365). B.P.S (IFI21/00024) holds an “iPFIS” predoctoral contract from the National System of Health, EU-ERDF-ISCIII. M.d.C.M.-P. holds predoctoral grants from the Spanish Ministry of Science, Innovation and Universities (FPU17/00276). P.R. (CP19/00068) holds a “Miguel Servet” research contract from the National System of Health, ISCIII co-funded by the European Social Fund, “Investing in your future,” Gobierno de España. This research was funded by Delegación del Gobierno para el Plan Nacional sobre Drogas, Ministerio de Salud, Gobierno de España (PND2020/048). Ethovision XT software v17 (Noldus, Wageningen, The Netherlands) funded by Plan Propio, Universidad de Málaga., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ribonucleotide reductase inhibition improves the symptoms of a Caenorhabditis elegans model of Alzheimer’s disease

  • Brokate-Llanos, Ana María
  • Sanchez-Ibañez, Mireya
  • Pérez-Jiménez, Mercedes M.
  • Monje-Moreno, José Manuel
  • Gómez-Marín, Carlos
  • Caro, Carlos
  • Vivar-Rios, Carlos
  • Moreno-Mateos, Miguel A.
  • García-Martín, María Luisa
  • Muñoz-Ruiz, Manuel Jesús
  • Royo, José Luis
Alzheimer's disease is the main cause of aging-associated dementia, for which there is no effective treatment. In this work, we reanalyze the information of a previous genome wide association study, using a new pipeline design to identify novel potential drugs. With this approach, ribonucleoside-diphosphate reductase gene (RRM2B) emerged as a candidate target and its inhibitor, 2′, 2′-difluoro 2′deoxycytidine (gemcitabine), as a potential pharmaceutical drug against Alzheimer's disease. We functionally verified the effect of inhibiting the RRM2B homolog, rnr-2, in an Alzheimer's model of Caenorhabditis elegans, which accumulates human Aβ1-42 peptide to an irreversible paralysis. RNA interference against rnr-2 and also treatment with 200 ng/ml of gemcitabine, showed an improvement of the phenotype. Gemcitabine treatment increased the intracellular ATP level 3.03 times, which may point to its mechanism of action. Gemcitabine has been extensively used in humans for cancer treatment but at higher concentrations. The 200 ng/ml concentration did not exert a significant effect over cell cycle, or affected cell viability when assayed in the microglia N13 cell line. Thus, the inhibitory drug of the RRM2B activity could be of potential use to treat Alzheimer's disease and particularly gemcitabine might be considered as a promising candidate to be repurposed for its treatment., MMPJ was granted with Fondo Europeo de Desarrollo Regional (FEDER) and the “Consejería de Universidad, Ciencia, Innovación y Universidades, Junta de Andalucía” Project UPO-1266266. JLR was granted with the project UMA20-FEDERJA-133 and MJM by the Ministerio de Ciencia, Innovación y Universidades grant PID2020-120463RB-I00. Work in MAM-M was supported by grants PID2021-127535NB-I00, CEX2020-001088-M and RyC-2017-23041 funded by Ministerio de Ciencia, Innovación y Universidades/Agencia Estatal de Innovación/10.13039/501100011033 by “ERDF A way of making Europe” and by ESF Investing in your future, grant UPO1380590 funded by “ERDF A way of making Europe,” Universidad Pablo de Olavide, and Junta de Andalucía. CGM was funded with ayudas captacion, incorporación y movilidad de capital humano de I+D+i, Junta de Andalucía. POSTDOC 21_00667. The C. elegans assy unit of the University Pablo de Olavide funded part of the work., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2020-001088-M)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Monosaccharides improve symptoms of an animal model for type III galactosemia, through the activation of the insulin pathway

  • Lucas-Rodríguez, Patricia
  • Brokate-Llanos, Ana María
  • Hernández-Curiel, José Manuel
  • Murdoch, Piedad del Socorro
  • Garzón, Andrés
  • Carrión Rodríguez, Ángel Manuel
  • Muñoz-Ruiz, Manuel Jesús
Type III galactosemia is characterized by the inability to metabolize galactose due to deficiency of the UDP-galactose-4-epimerase (GALE) gene, which catalyzes the interconversion of UDP-Galactose and UDP-Glucose. Additionally, GALE interconverts UDP-N-Acetylgalactosamine and UDP-N-Acetylglucosamine. These four sugars are needed for glycosylation of biomolecules. GALE deletion is considered lethal, and all described patients carry hypomorphic mutations. Symptoms are diverse and can range from mild to severe, without effective treatment. We have previously generated a Caenorhabditis elegans model for type III galactosemia, which carries a hypomorphic mutation in the GALE gene homologue. In this model, we observed that the symptoms varied depending on the diet. The aim of this work is to identify which dietary metabolites might alleviate the symptoms of type III galactosemia. To identify the molecules responsible, we used a C. elegans model of type III galactosemia and a mouse model to test whether the respond to the treatment is conserved in mammals and thus could be a putative intervention in patients. We found that high levels of monosaccharides in the diet is responsible for the beneficial effect in the C. elegans model. This intervention generates an increase of gale-1 expression through activation of the insulin pathway which may explain the reduction of the symptoms in animals carrying hypomorphic mutations. The increase of the GALE gene expression after monosaccharides treatment is also conserved in mammals and if maintained in humans, monosaccharide treatment combined with monitorization of GALE expression could be included in the management of patients with type III galactosemia., PL, AMB and MJM have been funded partially by the Spanish Ministry of Science and Innovation, Grant number: PID2020-120463RB-I00. The C. elegans assay unit of the University Pablo de Olavide funded part of the work. https://www.upo.es/upotec/catalogo/salud/unidad-de-ensayos-validacion-actividad-biologica/. JMHC and AC have been funded by the Spanish Ministry of Economy and Competitiveness/FEDER BFU2017/89780; UPO/FEDER 1380756, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced RNA-targeting CRISPR-Cas technology in zebrafish

  • Moreno-Sánchez, Ismael
  • Hernández-Huertas, Luis
  • Nahón-Cano, Daniel
  • Martínez-García, Pedro Manuel
  • Treichel, Anthony J.
  • Gómez-Marín, Carlos
  • Tomás-Gallardo, Laura
  • Silva Pescador, Gabriel da
  • Kushawah, Gopal
  • Egidy, Rhonda
  • Perera, Anoja
  • Díaz Moscoso, Alejandro
  • Cano-Ruiz, Alejandra
  • Walker, John A.
  • Muñoz-Ruiz, Manuel Jesús
  • Holden, Kevin
  • Galcerán, Joan
  • Nieto, M. Ángela
  • Bazzini, Ariel A.
  • Moreno Mateos, Miguel Ángel
CRISPR-Cas13 RNA-targeting systems are widely used in basic and applied sciences. However, its application has recently generated controversy due to collateral activity in mammalian cells and mouse models. Moreover, its competence could be improved in vivo. Here, we optimized transient formulations as ribonucleoprotein complexes or mRNA-gRNA combinations to enhance the CRISPR-RfxCas13d system in zebrafish. We i) use chemically modified gRNAs to allow more penetrant loss-of-function phenotypes, ii) improve nuclear RNA targeting, and iii) compare different computational models and determine the most accurate to predict gRNA activity in vivo. Furthermore, we demonstrate that transient CRISPR-RfxCas13d can effectively deplete endogenous mRNAs in zebrafish embryos without inducing collateral effects, except when targeting extremely abundant and ectopic RNAs. Finally, we implement alternative RNA-targeting CRISPR-Cas systems such as CRISPR-Cas7-11 and CRISPR-DjCas13d. Altogether, these findings contribute to CRISPR-Cas technology optimization for RNA targeting in zebrafish through transient approaches and assist in the progression of in vivo applications., We thank all members of the Moreno-Mateos laboratory for their intellectual and technical support. This work was supported by Ramon y Cajal (RyC-2017-23041), PID2021-127535NB-I00, CNS2022-135564 and CEX2020-001088-M grants funded by MICIU/AEI/ 10.13039/501100011033 by “ERDF A way of making Europe” (“ERDF/EU”), and by ESF Investing in your future from Ministerio de Ciencia, Innovación y Universidades and European Union (M.A.M.-M.). This work has also been co-financed by the Spanish Ministry of Science and Innovation with funds from the European Union NextGenerationEU (PRTR-C17.I1) and the Regional Ministry of University, Research, and Innovation of the Autonomous Community of Andalusia within the framework of the Biotechnology Plan applied to Health. The Moreno-Mateos lab was also funded by the European Regional Development Fund (FEDER 80% of the total funding) by the Ministry of Economy, Knowledge, Business and University, of the Government of Andalusia, within the framework of the FEDER Andalusia 2014-2020 operational program within the objective “Promotion and generation of frontier knowledge and knowledge oriented to the challenges of society, development of emerging technologies (grant UPO-1380590)” and by the Fondo Europeo de Desarrollo Regional (FEDER) and Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía, within the operative program FEDER Andalucía 2014-2020 (01—Refuerzo de la investigación, el desarrollo tecnológico y la innovación, grant P20_00866). M.A.M.-M. was the recipient of the Genome Engineer Innovation 2019 Grant from Synthego. The CABD is an institution funded by University Pablo de Olavide, Consejo Superior de Investigaciones Científicas (CSIC), and Junta de Andalucía. I.M-S. was a recipient of the Margarita Salas Postdoctoral contract funded by “NextGenerationEU”, Plan de Recuperación, Transformación y Resilencia and Ministerio de Ciencia, Innovación y Universidades (recualificación del sistema universitario español 2021-2023, Pablo de Olavide University Call). L.H-H. and D.N-C. were recipients of Ayudas para contratos predoctorales para la formación de doctores (Ministerio de Ciencia e Innovación) funded by MICIU/AEI /10.13039/501100011033 and FSE invierte en tu futuro and FSE. C.G-M. was funded with Ayudas captación, incorporación y movilidad de capital humano de I+D+i, Junta de Andalucía (POSTDOC 21_00667). P.M.M.G. was funded by a postdoctoral fellowship from Junta de Andalucía (DOC_00397). This study was supported by the Stowers Institute for Medical Research. A.A.B. was awarded a US National Institutes of Health grant (NIH-R01 GM136849 and NIH R21OD034161). A.J.T. was supported by the US National Institute of Health: F31HD110268. This work was completed as part of thesis research for A.J.T. and G.dS.P., Graduate School of the Stowers Institute for Medical Research. This work was supported by grant PID2021-125682NB-I00 to M.A.N. funded by MICIU/AEI /10.13039/501100011033 and by FEDER, UE; funds were also provided by Instituto de Salud Carlos III (CIBERER, CB19/07/00038 to M.A.N.) and Generalitat Valenciana (Prometeo 2021/45). M.A.N. also acknowledges financial support from the Spanish State Research Agency, through the “Severo Ochoa Program” for Centres of Excellence in R&D Grant CEX2021-001165-S funded by MCIN/AEI/ 10.13039/501100011033. M.J.M. was supported by grant PID2020-120463RB-I00 funded by the Spanish Ministerio de Ciencia e Innovación. We thank our colleague Francisco J. Guerra (Stowers Institute and CABD) for the initial research on Cas7-11, Amanda Lawlor and Kate Hall (Stowers Institute) for their technical work on RNA sequencing, and Cielo Centola for the help with illustrations (CABD)., With funding from the Spanish government through the "María de Maeztu Unit of Excellence" accreditation (CEX2020-001088-M)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001165-S)., Peer reviewed, Modelo experimental animal, Modelo experimental alternativo-NAM, Peces - Peces de agua dulce., Embriones no protegidos por la ley - Embriones de Peces. Danio, Orycias